What is CJC-1295 Without DAC?
CJC-1295 Without DAC is a synthetic peptide (29 amino acids; MW ≈ 3,367.9 Da) developed through academic research as part of the growth hormone-releasing hormone (GHRH) analog family. The "Without DAC" designation refers to the absence of the Drug Affinity Complex modification present in its counterpart compound. It is intended strictly for laboratory and research purposes.
Molecular & Structural Profile
CJC-1295 Without DAC contains four amino acid substitutions relative to native GHRH (1-29), which provide enhanced resistance to enzymatic degradation by DPP-IV and other proteases in laboratory research. The absence of the DAC modification results in a shorter plasma half-life relative to the DAC-modified version — a property studied in comparative pharmacokinetic research.
Areas of Active Scientific Investigation
Receptor Pharmacology Research: Studies examining GHRH receptor (GHRHR) binding kinetics and signaling pathway activation.
Comparative Pharmacology: Research comparing CJC-1295 Without DAC with native GHRH (1-29) and related analogs.
Pharmacokinetic Studies: Investigations into peptide half-life and structural stability profiles in research models.
Endocrinology Research: Academic studies of pituitary signaling pathway activation in cellular models.
Regulatory & Research Context
CJC-1295 Without DAC is sold strictly for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or application of any kind. It is not approved by the FDA to diagnose, treat, cure, or prevent any disease or condition. Not for use in any living organism.
Scientific References
- Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism. 2006.
- Sackmann-Sala L, et al. Molecular and Cellular Endocrinology. 2009.
- PubMed: PMC3081323
Wholesale
